+Open data
-Basic information
Entry | Database: EMDB / ID: EMD-7902 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Title | REGN3471 antibody Fab in complex with Ebola virus GP | |||||||||
Map data | REGN3471 antibody Fab in complex with Ebola virus GP | |||||||||
Sample |
| |||||||||
Biological species | Ebola virus - Mayinga, Zaire, 1976 | |||||||||
Method | single particle reconstruction / negative staining / Resolution: 21.0 Å | |||||||||
Authors | Turner H / Murin CD / Ward AB | |||||||||
Citation | Journal: J Infect Dis / Year: 2018 Title: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. Authors: Kristen E Pascal / Drew Dudgeon / John C Trefry / Manu Anantpadma / Yasuteru Sakurai / Charles D Murin / Hannah L Turner / Jeanette Fairhurst / Marcela Torres / Ashique Rafique / Ying Yan / ...Authors: Kristen E Pascal / Drew Dudgeon / John C Trefry / Manu Anantpadma / Yasuteru Sakurai / Charles D Murin / Hannah L Turner / Jeanette Fairhurst / Marcela Torres / Ashique Rafique / Ying Yan / Ashok Badithe / Kevin Yu / Terra Potocky / Sandra L Bixler / Taylor B Chance / William D Pratt / Franco D Rossi / Joshua D Shamblin / Suzanne E Wollen / Justine M Zelko / Ricardo Carrion / Gabriella Worwa / Hilary M Staples / Darya Burakov / Robert Babb / Gang Chen / Joel Martin / Tammy T Huang / Karl Erlandson / Melissa S Willis / Kimberly Armstrong / Thomas M Dreier / Andrew B Ward / Robert A Davey / Margaret L M Pitt / Leah Lipsich / Peter Mason / William Olson / Neil Stahl / Christos A Kyratsous / Abstract: BACKGROUND: For most classes of drugs, rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety, ...BACKGROUND: For most classes of drugs, rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety, and pharmacokinetic profiles. Fully human monoclonal antibodies (mAbs) provide an attractive method to overcome many of these hurdles to rapidly produce therapeutics for emerging diseases. METHODS: In this study, we deployed a platform to generate, test, and develop fully human antibodies to Zaire ebolavirus. We obtained specific anti-Ebola virus (EBOV) antibodies by immunizing ...METHODS: In this study, we deployed a platform to generate, test, and develop fully human antibodies to Zaire ebolavirus. We obtained specific anti-Ebola virus (EBOV) antibodies by immunizing VelocImmune mice that use human immunoglobulin variable regions in their humoral responses. RESULTS: Of the antibody clones isolated, 3 were selected as best at neutralizing EBOV and triggering FcγRIIIa. Binding studies and negative-stain electron microscopy revealed that the 3 selected ...RESULTS: Of the antibody clones isolated, 3 were selected as best at neutralizing EBOV and triggering FcγRIIIa. Binding studies and negative-stain electron microscopy revealed that the 3 selected antibodies bind to non-overlapping epitopes, including a potentially new protective epitope not targeted by other antibody-based treatments. When combined, a single dose of a cocktail of the 3 antibodies protected nonhuman primates (NHPs) from EBOV disease even after disease symptoms were apparent. CONCLUSIONS: This antibody cocktail provides complementary mechanisms of actions, incorporates novel specificities, and demonstrates high-level postexposure protection from lethal EBOV disease in ...CONCLUSIONS: This antibody cocktail provides complementary mechanisms of actions, incorporates novel specificities, and demonstrates high-level postexposure protection from lethal EBOV disease in NHPs. It is now undergoing testing in normal healthy volunteers in preparation for potential use in future Ebola epidemics. | |||||||||
History |
|
-Structure visualization
Movie |
Movie viewer |
---|---|
Structure viewer | EM map: SurfViewMolmilJmol/JSmol |
Supplemental images |
-Downloads & links
-EMDB archive
Map data | emd_7902.map.gz | 1.5 MB | EMDB map data format | |
---|---|---|---|---|
Header (meta data) | emd-7902-v30.xml emd-7902.xml | 13.1 KB 13.1 KB | Display Display | EMDB header |
Images | emd_7902.png | 63.1 KB | ||
Archive directory | http://ftp.pdbj.org/pub/emdb/structures/EMD-7902 ftp://ftp.pdbj.org/pub/emdb/structures/EMD-7902 | HTTPS FTP |
-Validation report
Summary document | emd_7902_validation.pdf.gz | 77.5 KB | Display | EMDB validaton report |
---|---|---|---|---|
Full document | emd_7902_full_validation.pdf.gz | 76.6 KB | Display | |
Data in XML | emd_7902_validation.xml.gz | 493 B | Display | |
Arichive directory | https://ftp.pdbj.org/pub/emdb/validation_reports/EMD-7902 ftp://ftp.pdbj.org/pub/emdb/validation_reports/EMD-7902 | HTTPS FTP |
-Related structure data
-Links
EMDB pages | EMDB (EBI/PDBe) / EMDataResource |
---|
-Map
File | Download / File: emd_7902.map.gz / Format: CCP4 / Size: 2 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | REGN3471 antibody Fab in complex with Ebola virus GP | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Voxel size | X=Y=Z: 4.1 Å | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Density |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Details | EMDB XML:
CCP4 map header:
|
-Supplemental data
-Sample components
-Entire : REGN3471 antibody Fab in complex with Ebola virus GP
Entire | Name: REGN3471 antibody Fab in complex with Ebola virus GP |
---|---|
Components |
|
-Supramolecule #1: REGN3471 antibody Fab in complex with Ebola virus GP
Supramolecule | Name: REGN3471 antibody Fab in complex with Ebola virus GP / type: complex / ID: 1 / Parent: 0 Details: Fab fragment generated by proteolytic cleavage of IgG antibody with papain. |
---|---|
Source (natural) | Organism: Ebola virus - Mayinga, Zaire, 1976 |
Recombinant expression | Organism: Drosophila melanogaster (fruit fly) / Recombinant cell: S2 / Recombinant plasmid: pMT-puro |
-Experimental details
-Structure determination
Method | negative staining |
---|---|
Processing | single particle reconstruction |
Aggregation state | particle |
-Sample preparation
Concentration | 0.02 mg/mL | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Buffer | pH: 7.4 Component:
Details: Solution was made from 10x concentration stock. | |||||||||
Staining | Type: NEGATIVE / Material: uranyl formate Details: Stained using 2% uranyl formate on carbon-coated grids. | |||||||||
Grid | Model: Homemade / Material: COPPER / Mesh: 400 / Support film - Material: CARBON / Support film - topology: CONTINUOUS / Pretreatment - Type: PLASMA CLEANING / Pretreatment - Atmosphere: OTHER | |||||||||
Details | This sample was monodisperse. |
-Electron microscopy
Microscope | FEI TECNAI SPIRIT |
---|---|
Image recording | Film or detector model: TVIPS TEMCAM-F416 (4k x 4k) / Digitization - Dimensions - Width: 4096 pixel / Digitization - Dimensions - Height: 4096 pixel / Number grids imaged: 1 / Number real images: 70 / Average exposure time: 0.6 sec. / Average electron dose: 30.0 e/Å2 |
Electron beam | Acceleration voltage: 120 kV / Electron source: LAB6 |
Electron optics | C2 aperture diameter: 100.0 µm / Illumination mode: FLOOD BEAM / Imaging mode: BRIGHT FIELD / Cs: 2.2 mm / Nominal defocus min: 1.0 µm / Nominal magnification: 52000 |
Sample stage | Specimen holder model: SIDE ENTRY, EUCENTRIC |
Experimental equipment | Model: Tecnai Spirit / Image courtesy: FEI Company |
-Image processing
Startup model | Type of model: OTHER / Details: Common lines model |
---|---|
Final reconstruction | Applied symmetry - Point group: C3 (3 fold cyclic) / Resolution.type: BY AUTHOR / Resolution: 21.0 Å / Resolution method: FSC 0.5 CUT-OFF / Software - Name: EMAN2 (ver. 2.1) / Number images used: 20266 |
Initial angle assignment | Type: COMMON LINE / Software - Name: EMAN2 |
Final angle assignment | Type: ANGULAR RECONSTITUTION / Software - Name: EMAN2 |